<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03455816</url>
  </required_header>
  <id_info>
    <org_study_id>Social Diabetes</org_study_id>
    <nct_id>NCT03455816</nct_id>
  </id_info>
  <brief_title>Clinical Study to Evaluate the Bio-Psychosocial Impact of Mobile App for Diabetes Type 1 (&quot;SOCIAL DIABETES&quot;)</brief_title>
  <official_title>Randomized Clinical Study to Evaluate the Bio-Psychosocial Impact of a Mobile App for Diabetes (&quot;SOCIAL DIABETES&quot;) and a SMARTMETER® (A. MENARINI DIAGNOSTICS) in the Care of People With Diabetes Mellitus Type 1 and Its Associated Costs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Soledad Ruiz de Adana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Based on international recommendations, the current clinical research project considers the
      effectiveness of a free diabetes app with a CE (Conformité Européenne) mark, &quot;Social
      Diabetes&quot;, which incorporates the addition of a glucometer (&quot;Glucomen Areo&quot;) it allows using
      NFC technology the automatic introduction of data, evaluating the impact on metabolic results
      and other related psychosocial variables, in people with diabetes 1 through a randomized
      randomized study during 6 months of follow-up.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized study in people with type 1 diabetes in intensive insulin therapy MDI with
      analogues and with HbA1c&gt; 7% to the usual clinical follow-up options (CG) vs use of Social
      Diabetes App (GI) for 6 months.

      The current clinical research project considers the effectiveness of a free diabetes app with
      a CE mark, &quot;Social Diabetes&quot;, which incorporates the addition of a glucometer (&quot;Glucomen
      Areo&quot;) it allows using NFC (Near Field Communication) technology the automatic introduction
      of data, evaluating the impact on metabolic results and other related psychosocial variables,
      in people with diabetes 1.

      The substitution of the usual face-to-face medical visit every 3-4 months by the
      incorporation of an app system has a similar effect in terms of glycemic control (measured
      through HbA1c) in patients with DM1 treated with multiple doses of insulin per day (MDI). )
      and inadequate metabolic control (HbA1c&gt; 7%). In addition, it could save costs and
      consumption of health resources, and improve both the quality of life and the satisfaction of
      people with DM1.

      The present study will be carried out under the usual conditions of clinical practice.

      No pharmacological intervention, other than the usual clinical practice, will be applied to
      the included patients.

      The people with diabetes 1 included in the study have a profile of &quot;expert patient&quot; having
      completed their diabetological education program at basic and advanced level (count of
      rations, calculations of ratios and sensitivity indexes) in such a way that the application
      will only be an aid in your daily decision making (mathematical calculations of ratios, IS,
      and recommended insulin doses, which you usually have to do &quot;by hand&quot;).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 7, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>glycosylated hemoglobin</measure>
    <time_frame>6 month</time_frame>
    <description>Metabolic impact measured through HbA1c of a mobile application (Social Diabetes) in the care of people with DM1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life assessment: Diabetes Quality of Life (DQoL) questionnaire.</measure>
    <time_frame>6 month</time_frame>
    <description>34 items to analyze the biopsychosocial impact measured through the quality of life questionnaire (DQol) of a mobile application (Social Diabetes) in the care of people with DM1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean blood glucose</measure>
    <time_frame>6 month</time_frame>
    <description>Glycemic control: Mean blood glucose measured in mg / dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standard deviation</measure>
    <time_frame>6 month</time_frame>
    <description>Glycemic variability: Standard deviation ( SD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of mild hypoglycaemia</measure>
    <time_frame>6 month</time_frame>
    <description>Number of mild hypoglycemia in two weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of severe hypoglycaemia</measure>
    <time_frame>6 month</time_frame>
    <description>Number of severe hypoglycaemia in the last 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hyperglycemia</measure>
    <time_frame>6 month</time_frame>
    <description>Number of hyperglycemia greater than 250mg / dl in two weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Episodes of ketosis</measure>
    <time_frame>6 month</time_frame>
    <description>Number of episodes of ketosis in the last 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Episodes of ketoacidosis</measure>
    <time_frame>6 month</time_frame>
    <description>Number of episodes of ketoacidosis in the last 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospital admissions for glycemic decompensation</measure>
    <time_frame>6 month</time_frame>
    <description>Number of hospital admissions for glycemic decompensation in the last 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fear of hypoglycemia: Questionnaire FH-15</measure>
    <time_frame>6 month</time_frame>
    <description>Fear of hypoglycemia: measured with the FH-15 scale. 15 items related to the fear of hypoglycemia in patients with type 1 diabetes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diabetes treatment satisfaction questionnaire ( DTSQ)</measure>
    <time_frame>6 month</time_frame>
    <description>8 items concerning the satisfaction of the treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diabetes distress scale. DDS</measure>
    <time_frame>6 month</time_frame>
    <description>17 items on the problems and stress that people with type 1 diabetes suffer (Polonski y col,2005)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scale of adherence to treatment in patients with diabetes type 1</measure>
    <time_frame>6 month</time_frame>
    <description>15 items related to adherence to patient treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">148</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>Group that uses the Social Diabetes App (research group)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group use the App Social diabetes with the glucometer Glucomen Areo to monitoring the glucemia during 6 month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual clinical monitoring group (control group)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group does not use the App. This group have an intermediate visit at 3 months with de doctor to see blood glucose self-monitoring and propose adjustments</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Social Diabetes App</intervention_name>
    <description>Social diabetes is an app for diabetes, free with CE mark, that by means of the incorporation of a glucometer (&quot;glucomen Areo&quot;) allows through NFC technology the automatic introduction of data in the application</description>
    <arm_group_label>Group that uses the Social Diabetes App (research group)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Usual clinical monitoring group (Control group)</intervention_name>
    <description>Active Comparator: Usual clinical monitoring group (control group) This group does not use the App. This group have an intermediate visit at 3 months with de doctor to see blood glucose self-monitoring and propose adjustments</description>
    <arm_group_label>Usual clinical monitoring group (control group)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with DM1 over 1 year evolution.

          -  Age ≥18 and &lt;65 years.

          -  HbA1c prior to the inclusion of the study&gt; 7%.

          -  Intensive insulin treatment with MDI in basal-bolus regimen.

          -  Patients with basic digital skills and with 3G mobile phone and NFC technology.

          -  Patients who have given their informed consent in writing.

        Exclusion Criteria:

          -  Treatment with subcutaneous insulin infusor (ISCI)

          -  Chronic kidney disease, liver disease, thyroid dysfunction (except hypothyroidism
             correctly treated and controlled).

          -  Pregnancy or pregnancy planning.

          -  Diabetes mellitus type 2.

          -  Severe psychological alterations.

          -  Absence of collaboration (informed consent).

          -  Patients who are participating in other clinical studies.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Maria Soledad Ruiz de Adana, MD PhD</last_name>
    <phone>+34 629221089</phone>
    <email>solruizdeadana@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Regional University Hospital of Málaga</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Soledad Ruiz de Adana, MD PhD</last_name>
      <phone>+34 629221089</phone>
      <email>solruizdeadana@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Virginia Morillas Jiménez, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://pewinternet.org/Reports/2012/Smartphone-Update-2012</url>
    <description>Smith A. Pew Internet &amp; American Life Project. Washington, DC 20036: Pew Research Center; 2012 Mar 01. Nearly half of American adults are Smart phone owners</description>
  </link>
  <reference>
    <citation>Lewis TL, Boissaud-Cooke MA, Aungst TD, Eysenbach G. Consensus on use of the term &quot;App&quot; versus &quot;Application&quot; for reporting of mHealth research. J Med Internet Res. 2014 Jul 17;16(7):e174; discussion e174. doi: 10.2196/jmir.3460.</citation>
    <PMID>25033233</PMID>
  </reference>
  <reference>
    <citation>Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, Rand L, Siebert C. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993 Sep 30;329(14):977-86.</citation>
    <PMID>8366922</PMID>
  </reference>
  <reference>
    <citation>Franc S, Daoudi A, Mounier S, Boucherie B, Dardari D, Laroye H, Neraud B, Requeda E, Canipel L, Charpentier G. Telemedicine and diabetes: achievements and prospects. Diabetes Metab. 2011 Dec;37(6):463-76. doi: 10.1016/j.diabet.2011.06.006. Epub 2011 Sep 1. Review.</citation>
    <PMID>21889388</PMID>
  </reference>
  <reference>
    <citation>Stone AA, Shiffman S, Schwartz JE, Broderick JE, Hufford MR. Patient non-compliance with paper diaries. BMJ. 2002 May 18;324(7347):1193-4.</citation>
    <PMID>12016186</PMID>
  </reference>
  <reference>
    <citation>Holtz B, Lauckner C. Diabetes management via mobile phones: a systematic review. Telemed J E Health. 2012 Apr;18(3):175-84. doi: 10.1089/tmj.2011.0119. Epub 2012 Feb 22. Review.</citation>
    <PMID>22356525</PMID>
  </reference>
  <reference>
    <citation>Chomutare T, Fernandez-Luque L, Arsand E, Hartvigsen G. Features of mobile diabetes applications: review of the literature and analysis of current applications compared against evidence-based guidelines. J Med Internet Res. 2011 Sep 22;13(3):e65. doi: 10.2196/jmir.1874. Review.</citation>
    <PMID>21979293</PMID>
  </reference>
  <reference>
    <citation>Charpentier G, Benhamou PY, Dardari D, Clergeot A, Franc S, Schaepelynck-Belicar P, Catargi B, Melki V, Chaillous L, Farret A, Bosson JL, Penfornis A; TeleDiab Study Group. The Diabeo software enabling individualized insulin dose adjustments combined with telemedicine support improves HbA1c in poorly controlled type 1 diabetic patients: a 6-month, randomized, open-label, parallel-group, multicenter trial (TeleDiab 1 Study). Diabetes Care. 2011 Mar;34(3):533-9. doi: 10.2337/dc10-1259. Epub 2011 Jan 25.</citation>
    <PMID>21266648</PMID>
  </reference>
  <reference>
    <citation>Kirwan M, Vandelanotte C, Fenning A, Duncan MJ. Diabetes self-management smartphone application for adults with type 1 diabetes: randomized controlled trial. J Med Internet Res. 2013 Nov 13;15(11):e235. doi: 10.2196/jmir.2588.</citation>
    <PMID>24225149</PMID>
  </reference>
  <reference>
    <citation>Vahatalo M. Cellular phone transferred self blood glucose monitoring: Prerequisites for positive outcome. Practical Diabetes International 2004;21(5):192-194.</citation>
  </reference>
  <reference>
    <citation>Gómez EJ, Hernando Pérez ME, Vering T, Rigla Cros M, Bott O, García-Sáez G, Pretschner P, Brugués E, Schnell O, Patte C, Bergmann J, Dudde R, de Leiva A. The INCA system: a further step towards a telemedical artificial pancreas. IEEE Trans Inf Technol Biomed. 2008 Jul;12(4):470-9. doi: 10.1109/TITB.2007.902162.</citation>
    <PMID>18632327</PMID>
  </reference>
  <reference>
    <citation>Benhamou PY, Melki V, Boizel R, Perreal F, Quesada JL, Bessieres-Lacombe S, Bosson JL, Halimi S, Hanaire H. One-year efficacy and safety of Web-based follow-up using cellular phone in type 1 diabetic patients under insulin pump therapy: the PumpNet study. Diabetes Metab. 2007 Jun;33(3):220-6. Epub 2007 Mar 28.</citation>
    <PMID>17395516</PMID>
  </reference>
  <reference>
    <citation>Cafazzo JA, Casselman M, Hamming N, Katzman DK, Palmert MR. Design of an mHealth app for the self-management of adolescent type 1 diabetes: a pilot study. J Med Internet Res. 2012 May 8;14(3):e70. doi: 10.2196/jmir.2058.</citation>
    <PMID>22564332</PMID>
  </reference>
  <reference>
    <citation>Frøisland DH, Arsand E, Skårderud F. Improving diabetes care for young people with type 1 diabetes through visual learning on mobile phones: mixed-methods study. J Med Internet Res. 2012 Aug 6;14(4):e111. doi: 10.2196/jmir.2155.</citation>
    <PMID>22868871</PMID>
  </reference>
  <reference>
    <citation>Piette JD. Interactive behavior change technology to support diabetes self-management: where do we stand? Diabetes Care. 2007 Oct;30(10):2425-32. Epub 2007 Jun 22.</citation>
    <PMID>17586735</PMID>
  </reference>
  <reference>
    <citation>Montori VM, Helgemoe PK, Guyatt GH, Dean DS, Leung TW, Smith SA, Kudva YC. Telecare for patients with type 1 diabetes and inadequate glycemic control: a randomized controlled trial and meta-analysis. Diabetes Care. 2004 May;27(5):1088-94.</citation>
    <PMID>15111526</PMID>
  </reference>
  <reference>
    <citation>Liang X, Wang Q, Yang X, Cao J, Chen J, Mo X, Huang J, Wang L, Gu D. Effect of mobile phone intervention for diabetes on glycaemic control: a meta-analysis. Diabet Med. 2011 Apr;28(4):455-63. doi: 10.1111/j.1464-5491.2010.03180.x.</citation>
    <PMID>21392066</PMID>
  </reference>
  <reference>
    <citation>Mulvaney SA, Ritterband LM, Bosslet L. Mobile intervention design in diabetes: review and recommendations. Curr Diab Rep. 2011 Dec;11(6):486-93. doi: 10.1007/s11892-011-0230-y. Review.</citation>
    <PMID>21960031</PMID>
  </reference>
  <reference>
    <citation>Wei J, Hollin I, Kachnowski S. A review of the use of mobile phone text messaging in clinical and healthy behaviour interventions. J Telemed Telecare. 2011;17(1):41-8. doi: 10.1258/jtt.2010.100322. Epub 2010 Nov 19. Review.</citation>
    <PMID>21097565</PMID>
  </reference>
  <reference>
    <citation>Krishna S, Boren SA, Balas EA. Healthcare via cell phones: a systematic review. Telemed J E Health. 2009 Apr;15(3):231-40. doi: 10.1089/tmj.2008.0099. Review.</citation>
    <PMID>19382860</PMID>
  </reference>
  <reference>
    <citation>Lee E, Tatara N, Arsand E, Hartvigsen G. Review of mobile terminal-based tools for diabetes diet management. Stud Health Technol Inform. 2011;169:23-7. Review.</citation>
    <PMID>21893707</PMID>
  </reference>
  <reference>
    <citation>Quinn CC, Shardell MD, Terrin ML, Barr EA, Ballew SH, Gruber-Baldini AL. Cluster-randomized trial of a mobile phone personalized behavioral intervention for blood glucose control. Diabetes Care. 2011 Sep;34(9):1934-42. doi: 10.2337/dc11-0366. Epub 2011 Jul 25. Erratum in: Diabetes Care. 2013 Nov;36(11):3850.</citation>
    <PMID>21788632</PMID>
  </reference>
  <reference>
    <citation>Whitehead L, Seaton P. The Effectiveness of Self-Management Mobile Phone and Tablet Apps in Long-term Condition Management: A Systematic Review. J Med Internet Res. 2016 May 16;18(5):e97. doi: 10.2196/jmir.4883. Review.</citation>
    <PMID>27185295</PMID>
  </reference>
  <reference>
    <citation>Holmen H, Torbjørnsen A, Wahl AK, Jenum AK, Småstuen MC, Arsand E, Ribu L. A Mobile Health Intervention for Self-Management and Lifestyle Change for Persons With Type 2 Diabetes, Part 2: One-Year Results From the Norwegian Randomized Controlled Trial RENEWING HEALTH. JMIR Mhealth Uhealth. 2014 Dec 11;2(4):e57. doi: 10.2196/mhealth.3882.</citation>
    <PMID>25499872</PMID>
  </reference>
  <reference>
    <citation>Waki K, Fujita H, Uchimura Y, Omae K, Aramaki E, Kato S, Lee H, Kobayashi H, Kadowaki T, Ohe K. DialBetics: A Novel Smartphone-based Self-management Support System for Type 2 Diabetes Patients. J Diabetes Sci Technol. 2014 Mar;8(2):209-215. Epub 2014 Mar 13.</citation>
    <PMID>24876569</PMID>
  </reference>
  <reference>
    <citation>Anarte Ortiz MT, Caballero FF, Ruiz de Adana MS, Rondán RM, Carreira M, Domínguez-López M, Machado A, Gonzalo-Marín M, Tapia MJ, Valdés S, González-Romero S, Soriguer FC. Development of a new fear of hypoglycemia scale: FH-15. Psychol Assess. 2011 Jun;23(2):398-405. doi: 10.1037/a0021927.</citation>
    <PMID>21381839</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2018</study_first_submitted>
  <study_first_submitted_qc>February 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 7, 2018</study_first_posted>
  <last_update_submitted>March 11, 2018</last_update_submitted>
  <last_update_submitted_qc>March 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud</investigator_affiliation>
    <investigator_full_name>Soledad Ruiz de Adana</investigator_full_name>
    <investigator_title>Maria Soledad Ruiz de Adana</investigator_title>
  </responsible_party>
  <keyword>mobile app</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

